Company profile: Intradigm
1.1 - Company Overview
Company description
- Provider of RNA interference (RNAi) therapeutics for the treatment of serious diseases, with an initial focus on oncology. The private biotechnology company leverages drug development and delivery expertise as the foundation of its RNAi platform, including a proprietary RNAi Nanoplex delivery.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intradigm
CatalYm
HQ: Germany
Website
- Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CatalYm company profile →
Xspray Pharma
HQ: Sweden
Website
- Description: Provider of improved and generic versions of marketed protein kinase inhibitors, using patented Hynap Technology to create amorphous formulations for faster post-patent entry. Portfolio includes Dasynoc (improved dasatinib for CML/ALL with lower dose, reduced absorption variability, and gastric acid suppressant compatibility), XS004 (dasatinib), and XS025 (cabozantinib for renal cell carcinoma and other cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xspray Pharma company profile →
Indaptus Therapeutics
HQ: United States
Website
- Description: Provider of an immunotherapy platform leveraging attenuated and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune pathways for anti-tumor and anti-viral activity. Offers Decoy20, a Phase 1 therapeutic candidate using engineered bacteria to stimulate anti-tumor defenses, and an intravenous pipeline targeting cancers and infectious diseases with high unmet needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indaptus Therapeutics company profile →
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
Kymera Therapeutics
HQ: United States
Website
- Description: Provider of targeted protein degradation therapeutics, leveraging TPD to eliminate disease-causing proteins, developing investigational degraders KT-474 (IRAK4) in Phase 2 for hidradenitis suppurativa and atopic dermatitis; KT-333 (STAT3) in Phase 1 for hematological malignancies and solid tumors; and KT-253 (MDM2) in Phase 1 for high-grade myeloid malignancies, lymphomas, and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymera Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intradigm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intradigm
2.2 - Growth funds investing in similar companies to Intradigm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intradigm
4.2 - Public trading comparable groups for Intradigm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →